Interestingly, T-cell dependent myeloma control in the setting of auto-HSCT (i.e., autologous graft-versus-tumor effect against neoplastic PCs) has formally been demonstrated in Vk*MYC myeloma-bearing mice, showing protective CD8+ T cells with a distinct T-cell receptor (TCR) repertoire and higher clonotype overlap, compared to controls [23,24]. Here, CD8A is linked to neoplasm.